Mankind Pharma is unlocking new vertical through BSV acquisition. It has access to a high-entry barrier business with multiple moats, healthy mix of domestic & intnl segments & sustainable EBITDA growth of 27%. EPS-accretive from 2nd year. TP ₹2650 (+24%)…
Mankind Pharma is unlocking new vertical through BSV acquisition
| Subscribe To Our Free Newsletter |
